Versant Venture Management, LLC
Position in GLUE — Monte Rosa Therapeutics, Inc.
CIK 1560009
San Francisco, CA
Position in GLUE
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$76,974,876
+$24,651,045 QoQ
Shares Held
3,180,780
0.0% QoQ
Ownership
3.73%
of shares outstanding
% of Portfolio
47.69%
of 13F equity value
Holder Rank
#11
of 192 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in GLUE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Versant Venture Management, LLC holds $161,394,736 across 8 Biotechnology names. GLUE ranks #1 (47.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GLUE |
Monte Rosa Therapeutics, Inc.
This page
|
3,180,780 | $76,974,876 | |
| 2 | IPSC |
Century Therapeutics, Inc.
|
12,166,109 | $29,806,967 | |
| 3 | JBIO |
Jade Biosciences, Inc.
|
991,783 | $22,037,418 | |
| 4 | LENZ |
LENZ Therapeutics, Inc.
|
2,656,888 | $15,091,123 | |
| 5 | CTNM |
Contineum Therapeutics, Inc.
|
542,628 | $8,893,672 | |
| 6 | CRSP |
CRISPR Therapeutics AG
|
148,831 | $8,117,242 | |
| 7 | TPST |
Tempest Therapeutics, Inc.
|
269,772 | $299,446 | |
| 8 | SKYE |
Skye Bioscience, Inc.
|
250,963 | $173,992 |
All Filings in GLUE
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $76,974,876 | 3,180,780 | Shares | Other | 2026-08-12 | |
| 2026-03-31 | $52,323,831 | 3,180,780 | Shares | Other | 2026-05-05 | |
| 2025-12-31 | $68,720,532 | 4,382,687 | Shares | Other | 2026-02-12 | |
| 2025-09-30 | $41,888,152 | 5,652,922 | Shares | Other | 2025-11-10 | |
| 2025-06-30 | $25,494,678 | 5,652,922 | Shares | Other | 2025-08-11 | |
| 2025-03-31 | $26,229,558 | 5,652,922 | Shares | Other | 2025-05-07 | |
| 2024-12-31 | $39,231,278 | 5,652,922 | Shares | Other | 2025-02-12 | |
| No filing history on record for this holder in this stock. | ||||||